FORBION CAPITAL PARTNERS
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
FORBION CAPITAL PARTNERS
Social Links:
Industry:
Biotechnology Health Care Venture Capital
Founded:
2006-01-01
Status:
Active
Contact:
+31 35 699 30 00
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag Mobile Non Scaleable Content Google Maps
Similar Organizations
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Polaris Partners
Polaris Partners is an investment firm that invests in healthcare and biotechnology companies.
Roche Venture Fund
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche.
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-04 | F2G | Forbion Capital Partners investment in Private Equity Round - F2G | 70 M USD |
| 2022-06-29 | VectivBio | Forbion Capital Partners investment in Post-IPO Equity - VectivBio | 54 M USD |
| 2022-03-16 | Precirix | Forbion Capital Partners investment in Series B - Precirix | 80 M EUR |
| 2022-02-23 | Complement Therapeutics | Forbion Capital Partners investment in Seed Round - Complement Therapeutics | 5 M EUR |
| 2021-12-20 | ARMGO,Pharma,Inc. | Forbion Capital Partners investment in Series B - ARMGO,Pharma,Inc. | 35 M USD |
| 2021-12-17 | NorthSea Therapeutics | Forbion Capital Partners investment in Series C - NorthSea Therapeutics | 80 M USD |
| 2021-12-16 | Anaveon | Forbion Capital Partners investment in Series B - Anaveon | 110 M CHF |
| 2021-11-03 | Prilenia | Forbion Capital Partners investment in Series B - Prilenia | 43 M USD |
| 2021-10-14 | Rectify Pharmaceuticals | Forbion Capital Partners investment in Series A - Rectify Pharmaceuticals | 100 M USD |
| 2021-07-07 | NeRRe Therapeutics | Forbion Capital Partners investment in Series B - NeRRe Therapeutics | 20 M GBP |
More informations about "Forbion Capital Partners"
About us - Forbion
Forbion then and now. Forbion was born out of ABN AMRO Capital Life Sciences. Today, to emphasize its value-add beyond merely providing capital, we are simply known as Forbion.For more than two decades, our investment team has built …See details»
Forbion Capital Partners - Crunchbase
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine …See details»
Forbion - LinkedIn
Forbion | 13,816 followers on LinkedIn. Impacting the future of medicine | Forbion was born out of ABN AMRO Capital Life Sciences in 2000. Six years later, we transitioned to Forbion Capital Partners.See details»
Forbion raises in excess of €2 billion for two new funds
Oct 15, 2024 Naarden, The Netherlands, October 15, 2024 – Forbion, a leading global life sciences venture capital firm with deep expertise in Europe, today announces that it has raised over €2 billion ($2.2 billion) across its two newest …See details»
Forbion Capital Partners - Investments, Portfolio & Company Exits
Forbion Capital Partners has made 6 diversity investments. Their most recent diversity investment was on Dec 20, 2021, when ARMGO Pharma raised. obfuscated. obfuscated. Announced …See details»
Forbion Capital Partners - Funding, Financials, Valuation & Investors
Forbion Capital Partners has raised a total of $6.1B across 12 funds, their latest being Forbion Ventures VII. This fund was announced on Oct 15, 2024 and raised a total of . obfuscated. …See details»
Forbion Capital Partners - Company Profile and News
Forbion Capital Partners operates as a venture capital firm. The Company invests in life sciences and biomedical technology companies, as well as offers investment management services.See details»
Forbion Capital Partners - EU-Startups
Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. …See details»
Forbion's €2B funds are largest yet, with 30 biotechs to benefit
Oct 15, 2024 Netherlands- and Germany-based Forbion exceeded its targets for its two newest funds, Forbion Growth Opportunities III and Forbion Ventures VII, by bringing in 1.2 billion …See details»
Forbion Capital Partners Portfolio Companies - Crunchbase
Jan 2, 2011 Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts. This list of organizations invested in by Forbion Capital Partners …See details»
Forbion announces first close of Forbion Growth Opportunities …
Jun 9, 2022 Forbion expects to reach its €600 million hard cap, completing the raising of Forbion Growth Opportunities Fund II over the summer. Sander Slootweg, Managing Partner and co …See details»
Forbion announces first close of Forbion Growth Opportunities …
Jul 9, 2020 “We will be looking to partner with world-class European companies and entrepreneurs to provide both capital and expertise, building the next generation of successful …See details»
Forbion raises €1.35 billion across two funds - Yahoo Finance
Apr 19, 2023 NAARDEN, The Netherlands and MUNICH, Germany, April 19, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, today …See details»
Forbion Capital Partners - Contacts, Employees, Board
Forbion Capital Partners has 17 current employee profiles, including Partner Rogier Rooswinkel. Forbion Capital Partners has 2 board members and advisors, including Kapil Dhingra. …See details»
Forbion announces first close of its new BioEconomy Fund I: …
Amsterdam, 20 June 2024 – Forbion, a leading life sciences venture capital firm, announces the first close of its latest fund, Forbion BioEconomy Fund I (“Forbion BioEconomy"), at €75 …See details»
Forbion aims new €470M late-stage fund at bets enabled by …
Jun 9, 2022 Forbion is back with another late-stage investment fund. Two years after making its first foray into the space, the VC shop has returned with a larger €470 million ($505 million) …See details»
Forbion Capital Partners - Updates, News, Events, Signals & Triggers
Forbion Capital Partners may be growing as evidenced by their significant ownership stake in a publicly traded company. The firm holds a 52% ownership in Dyne Therapeutics, Inc., a …See details»
Forbion announces final close of Forbion Growth Opportunities …
Apr 20, 2021 Naarden, The Netherlands and Munich, Germany – 20 April 2021 – Forbion, a leading European life sciences venture capital firm, today announces the final close of its …See details»
General Partner @ Forbion Capital Partners - Crunchbase
Marco is a Partner at Forbion Capital Partners investing in Life Science companies. He serves on the Board of RSPR Pharma and is an observer to the Board of Exosome Diagnostics and …See details»